Nephrotoxicity in Leukemic Patients Receiving Empirical Amphotericin B and Aminoglycosides
- 1 September 1988
- journal article
- research article
- Published by Southern Medical Association in Southern Medical Journal
- Vol. 81 (9) , 1095-1099
- https://doi.org/10.1097/00007611-198809000-00007
Abstract
Twelve leukemic patients (19%) receiving amphotericin B and aminoglycosides had nephrotoxicity (creatinine value > 2.0 mg/dl). Patients with nephrotoxicity tended to be older than patients without nephrotoxicity; gender and total amphotericin B dose were not related to nephrotoxicity. Sodium administration has previously been shown to reverse amphotericin B nephrotoxicity. In this series, among patients receiving ticarcillin at .gtoreq. 18 gm/day (93.6 mEq of sodium per day) the incidence of nephrotoxicity was significantly decreased (1/30, or 3.3%). A multivariate analysis showed that this protective effect of ticarcillin was not dependent on the fact that patients receiving ticarcillin were less likely to receive vancomycin. There were insufficient patients receiving sodium in the absence of ticarcillin to study the effect of sodium alone. However, our observations are consistent with the hypothesis that sodium can prevent renal dysfunction in this clinical situation.This publication has 4 references indexed in Scilit:
- Attenuation of experimental tobramycin nephrotoxicity by ticarcillinAntimicrobial Agents and Chemotherapy, 1985
- Clinical value of empirical amphotericin B in patients with acute myelogenous leukemiaCancer, 1982
- Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopeniaThe American Journal of Medicine, 1982
- THE INFLUENCE OF SODIUM STATUS AND FUROSEMIDE ON CANINE ACUTE AMPHOTERICIN-B NEPHROTOXICITY1980